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LEADING ARTICLE
Unravelling the complex genetics of inflammatory bowel
disease
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The rapid pace of progress in molecular genetics over the
past 15 years—since the seminal description of the
polymerase chain reaction—has led to the identification of
the genes involved in many single gene disorders. These
successes in the laboratory have already led directly to
clinical applications in diagnosis, pharmacogenetics, and
the development of new therapies. Progress in unravelling
the genetics of complex diseases has been less
straightforward. However, real excitement has followed the
identification of the NOD 2/CARD 15 gene as an
important determinant of susceptibility to Crohn’s
disease.1 2 Not only has this finding provided a proof of
principle for the technique of genome-wide scanning in
complex disorders, but the discovery also has given real
insight into the primary pathophysiology involved in
chronic inflammatory bowel disease. The background to
this discovery and its implications form the basis for the
present article.
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T
he chronic inflammatory bowel diseases,
Crohn’s disease and ulcerative colitis are
now common causes of gastrointestinal
morbidity in children and young adults in the
United Kingdom. Moreover, whereas incidence
rates in adults appeared to have stabilised in
recent years, compelling data both from our own
unit, and elsewhere in the United Kingdom,
suggest that the incidence of early onset cases in
children continues to rise.3–5 These studies have
shown a rise in the incidence of early onset
inflammatory bowel disease in Scottish children
from 2.6 cases per 100 000 population in 1968 to
6.5 cases per 100 000 population in 1999.
Crohn’s disease is characterised by patchy
transmural inflammation affecting any part of
the gastrointestinal tract, whereas ulcerative
colitis characteristically is limited to the colon,
producing continuous mucosal inflammation
always involving the rectum. Extra-intestinal
manifestations affecting the skin, joints, and
the eyes occur in both Crohn’s disease and
ulcerative colitis. Colorectal cancer is a recog-
nised complication of long standing colonic
involvement. A recent meta-analysis has sug-
gested the risk of colorectal cancer in children
with ulcerative colitis is double that of adult
onset disease.6 In a proportion of patients
suffering from inflammatory bowel disease
affecting the colon, it proves impossible to
distinguish between Crohn’s disease and ulcera-
tive colitis, even after colectomy, and a diagnosis
of indeterminate colitis is made.
In the 21st century, inflammatory bowel
disease has a great impact in both adult as well
as paediatric gastroenterology, related to the
morbidity of the illnesses and the therapies
now available. Growth impairment is a particular
feature in children but has effects lasting into
adult life, with up to 35% of subjects showing
evidence of permanent growth failure.7 In addi-
tion to growth problems, pubertal development,
education, employment potential, and quality of
life all suffer as a consequence of these chronic
disabling illnesses.
GENE-ENVIRONMENTAL INTERACTIONS
UNDERLIE THE PATHOGENESIS OF
INFLAMMATORY BOWEL DISEASE
There are strong epidemiological data to suggest
that both environmental and genetic influences
are involved in the pathogenesis of chronic
inflammatory bowel diseases, Crohn’s disease
and ulcerative colitis. The temporal trends in
incidence—in particular the increase in the
incidence of inflammatory bowel disease over
the past three decades in young people—cannot
be explained by the influence of genetic factors
alone. The environmental factors involved in
disease pathogenesis remain under investigation.
Smoking habit clearly influences susceptibility
to both Crohn’s disease and ulcerative colitis.8 9
However smoking habit has contrasting effects:
in Crohn’s disease smoking is associated with an
increased susceptibility to disease, rapid disease
progression, and further need for surgery and
immune suppression. In contrast, smoking is
protective against the development of ulcerative
colitis; dose-response relations have been identi-
fied. As most children do not smoke at the time
of inflammatory bowel disease diagnosis the role
of passive smoking is more relevant.
Lashner et al identified smoking at birth rather
than at the time of diagnosis of inflammatory
bowel disease as a risk factor both for the
development Crohn’s disease and ulcerative
colitis in childhood.10
Attempts to identify infective agents involved
in disease pathogenesis have attracted great
attention. The role of Mycobacterium paratubercu-
losis in the pathogenesis of Crohn’s disease
remains a subject of impassioned debate.11 The
results of a number of studies are awaited—
notably an MRC funded study in the United
Kingdom and a placebo controlled double
blinded study of anti-mycobacterial therapy
in Australia. The controversies regarding the
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measles virus and the MMR vaccine have been the subject of
an editorial in this journal, and have been evaluated in great
detail elsewhere.12 13 The most compelling evidence for the
involvement of microbial agents implicates the gut flora.
Animal models of colitis—genetically engineered, chemically
induced, or spontaneous—all require the presence of gut flora
in order for disease to become manifest.14 These data
complement clinical studies—the effect of faecal diversion
in Crohn’s disease, and increasing evidence that antibiotic
and probiotic therapy may attenuate disease.15 16
Diet, childhood deprivation, breast feeding, and passive
smoking all require to be evaluated in large well designed
studies of early onset inflammatory bowel disease.
EVIDENCE FOR GENETIC SUSCEPTIBILITY
Strong epidemiological data provided the basis for the recent
molecular genetic studies in inflammatory bowel disease. In
particular, ethnic differences in disease susceptibility, and
concordance rates in twin pairs and multiply affected families
all provided the catalyst for detailed evaluation of the
molecular genetics of Crohn’s disease and ulcerative colitis.
Ethnic differences in the susceptibility of inflammatory
bowel disease are well documented. The Ashkenazi Jewish
population, living in Western Europe and Northern America
have the highest reported prevalence rates, both of sporadic
and familial disease.17 In contrast, disease prevalence rates
are reported lower in Afro-Americans than in any other
ethnic group studied. It is likely that a combination of genetic
and environmental factors underlies the differences in
prevalence amongst ethnic groups; this complexity is best
illustrated by considering prevalence rates among Asian
migrants in the United Kingdom. Data from Leicester suggest
that the Asian population in the United Kingdom have an
increased susceptibility to ulcerative colitis, compared with
the indigenous population.18
Concordance rates in monozygotic and dizygotic twin pairs
provide further evidence for the importance of both genetic
and environmental facts. Three studies in Europe have
reported on 326 twin pairs,19–21 with recent follow up data
available from the first study.22 The overall concordance rates
for Crohn’s disease were 36%, and 4% (monozygotic and
dizygotic pairs respectively), with the corresponding results
for ulcerative colitis reported as 16% and 4%. This suggests a
greater genetic role in Crohn’s disease compared with
ulcerative colitis. The derived coefficient of heritability in
Crohn’s disease is equivalent to that reported for other
chronic childhood diseases including insulin dependent
diabetes and asthma.23
The prevalence of familial inflammatory bowel disease has
been studied widely. It is apparent that a positive family
history of inflammatory bowel disease is the best established
risk factor for development of disease. Although precise
estimates vary, consistent findings are present in the studies
that have been performed. Between 6% and 32% of patients
with inflammatory bowel disease have an affected relative.23
Siblings are at greatest risk with lower relative risks reported
for parents, offspring, and second degree relatives. In Crohn’s
disease, the relative risk to a sibling, compared with the
population prevalence, has been estimated as between 13 and
36. The equivalent figure in ulcerative colitis has been
estimated between 7 and 17. In the unusual situation of a
child being born to parents who both have inflammatory
bowel disease, they have a 33% chance of developing
inflammatory bowel disease by 28 years of age.24 Again these
data are consistent with a strong genetic component in
disease susceptibility.
A number of other points are notable from the studies of
familial disease. It is apparent that the relatives of patients
with Crohn’s disease are at an increased risk, not only of
Crohn’s disease, but also of ulcerative colitis, supporting
common predisposing factors to these phenotypes of inflam-
matory bowel disease.25 Moreover, not only susceptibility, but
also disease behaviour, appears to have a strong familial
basis.26 Finally, it is apparent that early onset disease has a
stronger familial and therefore perhaps genetic contribution.
These data are best illustrated by reviewing the Cleveland
Clinic study involving a large number of patients with early
onset disease in whom 35% had a positive family history.27
GENETIC MODEL
Although the epidemiological data suggest genetic factors
interact with the environment in disease pathogenesis, the
model whereby these interactions occur remains under
debate. Complex segregation analyses have suggested that a
simple recessive model of inheritance may be pertinent to
a small proportion of patients with Crohn’s disease, and a
simple dominant model pertinent to a proportion of patients
with ulcerative colitis. However, the model which has been
most widely accepted by the investigators at the present time
is that Crohn’s disease and ulcerative colitis are related
polygenic diseases, sharing some but not all susceptibility
genes. In addition, the variability of clinical presentation of
disease—disease phenotype—is likely to represent the effects
of allelic variations of these genes, and the interaction
between these allelic variations and environmental factors.
PROGRESS TOWARDS GENE IDENTIFICATION
Two complementary methods have been employed by
investigators searching for susceptibility genes in complex
diseases—candidate gene analysis and genome-wide scan-
ning. The analysis of candidate genes relies on an under-
standing of disease pathophysiology. In inflammatory bowel
disease for example, the immunopathology of the disease led
to examination of genes involved in the regulation of the
immune system, genes involved in the maintenance of
mucosal integrity, and genes involved in cell-cell interactions.
The frequency of allelic variants of these genes in patients
with inflammatory bowel disease is compared with allelic
frequencies in a well matched control population. A
significant distortion of frequencies in the groups under
comparison would provoke further investigation of the gene
of interest. Many candidate genes have been subject to
analysis in inflammatory bowel disease—notably the genes
of the HLA system, genes involved in the regulation of
cytokine production, mucin synthesis, and other aspects of
epithelial barrier function.
It is, however the complementary technique of genome-
wide scanning in which success has become most apparent.
The development of a linkage map of the human genome,
involving informative microsatellite markers provided a
framework for the systematic analysis of the human genome
in both single gene disorders, and complex diseases. Studies
in complex diseases have required access to large numbers of
multiply affected families (typically sibling pairs), semi-
automated technology for genotyping, and particularly the
evolution of techniques for analysis. The technique has been
applied by investigators in many common disorders—
encompassing metabolic, respiratory, cardiovascular, endo-
crine, and neuropsychiatric disease. In each disorder, a
number of linkages with regions throughout the genome
have been described. However, proceeding from the initial
observation of linkage through replication to gene identifica-
tion has defeated many investigators. Inflammatory bowel
disease has reached an enviable position. Four regions of the
genome have been replicated, with sufficient strength to
satisfy stringent criteria laid down by the statistical geneti-
cist.23 Moreover, progress has been most evident in pursing
The genetics of inflammatory bowel disease 599
www.archdischild.com
the IBD 1 locus on chromosome 16. Widespread replication
has been followed by gene identification.
OTHER IBD LOCI
IBD 2 is located on chromosome 12 and is the region most
strongly implicated from the only reported UK genome-wide
scan.28 A combination of a number of international studies
has failed to show strong support for inflammatory bowel
disease susceptibility linkage at this locus when Crohn’s
disease and ulcerative colitis are considered together.29
However, this region does show strongest linkage within
pure ulcerative colitis families, suggesting it is mainly an
ulcerative colitis susceptibility locus. No studies of the
candidate genes within this region, however, have shown
positive linkage with ulcerative colitis.30
IBD 3 is located on chromosome 6 surrounding the region
of the major histocompatibility complex. This not only
represents a susceptibility locus for ulcerative colitis and
Crohn’s disease, but also is implicated in determining disease
phenotype.31 This is shown in ulcerative colitis where
possession of the HLADRB1*0103 allele has association with
severe colitis and the presence of extra intestinal manifesta-
tions.32–34 There has also been considerable interest in IBD 3
because within this region lies the gene encoding tumour
necrosis factor a. Associations within the promoter region of
this gene have been linked to susceptibility to inflammatory
bowel disease.35 36
The IBD 4 locus is located on chromosome 14 and has been
implicated in susceptibility to Crohn’s disease in North
America and Europe.37 IBD 5 is a Crohn’s disease suscept-
ibility locus located at 5q31–33.38 By using a linkage
disequilibrium approach Rioux identified a common haplo-
type in this region spanning 250 kb that contains a cytokine
gene cluster. The risk for heterozygotes in possession of the
risk alleles was a twofold risk of Crohn’s disease and for
homozygotes, sixfold. Earlier age of onset of Crohn’s disease
was identified in those carrying the risk alleles.
A number of other sub-chromosomal regions have been
implicated by genome-wide scanning, including the X
chromosome linkage described in independent European
populations. The strength of linkage evidence for each of
these other putative loci is relatively weaker than for IBD 1–5,
but these may each contain determinants of susceptibility
or disease behaviour.30 39
IBD 1: FROM LINKAGE TO GENE
Jean Pierre Hugot, a paediatric gastroenterologist in Paris,
initially described the IBD 1 locus on chromosome 16, in a
landmark publication in 1996.40 The investigators described
linkage with Crohn’s disease to a region spanning the
centromere on chromosome 16. In spite of worries regarding
the relatively weak evidence of linkage, this linkage has been
reproduced widely, in Europe, North America, and most
strongly in the Australian population.41–46 An international
collaborative group pooled data from 12 centres, and
confirmed the strength of the linkage of chromosome 16.29
IBD 1 has now been confirmed as a Crohn’s disease locus
which has been linked to early onset severe disease.47
Between 1996 and 2001, investigators were attempting to
narrow the region of linkage and identify the gene lying
therein. Three parallel publications in May/June 2001
confirm the identity of the IBD 1 gene as nucleotide
oligomerisation domain (NOD) 2.1 2 48 NOD 2 was subse-
quently renamed caspase activating recruitment domain
(CARD) 15. Hugot and colleagues applied the classical
strategy of positional cloning to narrowing the region of
linkage, and were then able to construct a physical map
of the region. A study of markers within a physical
map involving bacterial artificial chromosomes led to the
identification of the NOD 2/CARD 15 gene. In Hugot’s initial
publication, allelic variants of the NOD 2/CARD 15 gene were
present in 43% of patients with Crohn’s disease. Three
polymorphisms were identified to be associated with Crohn’s
disease: two missense mutations Arg702Trp and Gly908Arg,
and a frameshift mutation Leu1007fsincC. A number of other
rarer mutations have been identified following more detailed
analysis.49 The frameshift mutation has been studied in
greatest depth, involving the insertion of a cytosine repeat in
exon 10 of the gene, which gives rise to a premature stop
codon and a truncated form of the NOD 2/CARD 15 protein.
It is of interest that Hugot’s data suggest that the NOD 2 gene
may act in a recessive mode of inheritance. The relative risk
for simple heterozygote is estimated at 3, whereas the risk for
simple homozygote is 38 and the risk for compound
heterozygote is quoted at 44. Patients possessing NOD 2
mutations are not at increased risk of ulcerative colitis.
Hugot’s data were mirrored by those from two other sets of
investigators. The investigators in the United States led by
Judy Cho and Gabriel Nunez were able to publish in the same
volume of Nature as Hugo and the European team.1 These
authors also concentrated on the insertion of a cytosine
repeat in exon 10, and were able to show that the allelic
frequencies of this insertion were significantly increased in
both Jewish and non-Jewish patients with Crohn’s disease
compared with healthy controls. Once again an increased risk
in homozygotes was very clear in this publication. Further
confirmatory data from Europe, including the first study in
the United Kingdom, followed from Schreiber’s group, based
in Kiel.48 Again these investigators concentrated on the
frameshift mutation and were able to show the mutations in
almost 20% of patients studied.
A flurry of confirmatory studies, involving more detailed
analysis of the gene and genotype-phenotype relations have
emerged (see table 1).
The data for Caucasian western populations contrast
starkly with that of Asian populations where NOD 2/
CARD 15 mutations have not been found in Crohn’s disease
patients, ulcerative colitis patients, or healthy controls.58 59
The wealth of data promises to lead to a molecular
reclassification of Crohn’s disease and inflammatory bowel
disease. It is apparent from very painstaking studies carried
out in France and the United Kingdom (both London and
Oxford) that NOD 2/CARD 15 mutations are associated with
susceptibility to Crohn’s disease, and that these mutations
may protect against the development of ulcerative colitis.50 52
Moreover, within Crohn’s disease, it is apparent that NOD 2/
CARD 15 mutations predisposed towards ileal disease, but
not colonic disease. Patients with NOD 2/CARD 15 mutations
have also been linked to stricturing disease behaviour, but
this may be a secondary phenomenon as stricturing is seen
most commonly as a complication of ileal disease location.
Several studies have linked NOD 2 mutations with earlier
disease onset.49 52 57 The data for specific paediatric popula-
tions, however, are only starting to emerge.60 The most
striking effect in early onset disease has been for homo-
zygotes/compound heterozygotes in which homozygotes
represent 34% of patients with an age of onset ,10 years,
compared with 3% with an onset of 40 years or more.61
NOD 2 FUNCTION AND DYSFUNCTION
Function of the wild type and mutant NOD 2/CARD 15 is
clearly an important focus for investigation. Initially it
appeared the NOD 2/CARD 15 gene was only expressed in
monocytes,62 but it is clear now that it is not only expressed in
all cells of the monocyte lineage but also in primary epithelial
cells and intestinal epithelial cells.63 Within the intestinal
epithelial cells the greatest concentration of NOD 2 mRNA is
found in Paneth cells both in healthy controls and in patients
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with Crohn’s disease.64 Patients with Crohn’s disease how-
ever have greater concentrations of NOD 2 mRNA in the
Paneth cells. Paneth cells are found in greatest concentration
within the ileum and may help explain the association of
NOD 2/CARD 15 mutations with terminal ileal disease.
Tumour necrosis factor a, an important pro-inflammatory
cytokine in Crohn’s disease has a key role in the regulation of
expression of NOD 2/CARD 15 within the intestinal epithelial
cells.65
The NOD 2/CARD 15 gene has structural homology with
plant disease resistant genes, and the toll-like receptor family
of genes which are involved in regulation of the innate
immune response. The NOD 2/CARD 15 gene contains three
regions: 2N-terminal CARDs which are involved in protein-
protein interactions, a centrally located nucleotide binding
domain which mediates self oligomerisation that is needed
for self activation, and at the C-terminal the leucine rich
repeat (LRR) domain that is important for binding of
bacteria. Wild type NOD 2/CARD 15 is involved in the
activation of nuclear factor-kB (NF-kB) which is triggered
by bacteria binding to the LRR.62 Specifically, it is muramyl
dipeptide, the minimal essential structure of bacterial
peptidoglycan that is recognised by the NOD 2/CARD 15
pathway within the cell.66 All three common mutations of the
NOD 2 gene result in failure of NF-kB activation after
muramyl dipeptide binding giving a uniform loss of function
as their mechanism of action. Figure 1 shows the interaction
of NOD 2/CARD 15 within the cell.
NOD 2/CARD 15 GENE-GENE INTERACTION
The interaction of NOD 2/CARD 15 mutations with other
genes is only starting to be explored. The gene at the IBD 5
locus has not been identified but two risk alleles on the IBD 5
haplotype have. Mirza et al were able to replicate the findings
of Rioux’s Canadian study in a British/German population,
but the increase Crohn’s disease risk in this population for
those in possession of the risk alleles was much smaller.67
Mirza et al also showed an earlier age of onset in those
possessing the risk alleles, an effect that was increased if
NOD 2/CARD 15 mutations were also present. The study
showed homozygotes for the risk alleles plus one CARD
mutation had a 58% chance of Crohn’s disease by age 21
compared with 27% who carried neither of the genotypes.
This figure had risen to 93% by age 36. This suggests
cooperation between IBD 5 and NOD 2/CARD 15 in disease
causation, giving evidence of gene-gene interaction, espe-
cially in an early onset population. Another British study has,
however, been unable to replicate these findings.68
NOD 2/CARD 15 MUTATIONS: ROLE IN OTHER
DISEASES
The identification of NOD 2/CARD 15 gene has lead to a
search for its role in other inflammatory conditions. Blau
syndrome is a rare disorder sharing some features in common
with Crohn’s disease characterised by skin rashes, uveitis,
arthritis, and granuloma formation. Mutations with the NBD
domain of the NOD 2/CARD 15 gene have been associated
with Blau syndrome, contrasting with Crohn’s disease where
the mutations are located in the LRR region.69 Negative
studies have been published for multiple sclerosis,70 ankylos-
ing spondylitis,71–73 systemic lupus erythematosus,74 rheuma-
toid arthritis,75 Wegener’s granulomatosis,76 and psoriasis.77
Interestingly a recent study of German schoolchildren
suggested NOD 2/CARD 15 mutations were more common
Table 1 Allele frequencies of common NOD 2 mutations in different populations
Population Arg702Trp Gly908Arg Leu1007 finsC Phenotype correlation
European2 11 6 12 ND
USA1 ND ND 8.2 ND
UK/German48 ND ND 16 ND
UK/German/Dutch50 9.1 3.4 6.6 Ileal/familial
Canadian51 12.9 5.2 10.3 Ileal
British52 12.5 3.3 9.4 Ileal/earlier onset
European49 11 6 11 Ileal/stricturing/earlier onset
Scottish53 7.1 1.8 4.7 No association found
Finnish54 3.3 0.6 4.8 Ileal/stricturing
Dutch55 ND ND 14 ND
Greek56 ND ND 2.7 ND
Irish57 7 3 4 Ileal/earlier onset
Figures in bold signify a significant difference in Crohn’s disease patients compared to healthy controls.
ND, not done.
Figure 1 The interaction of NOD 2/CARD 15 within the cell.
(Reprinted from Bonen DK et al. The genetics of inflammatory bowel
disease. Gastroenterology 2003;124(2):530, with permission from the
American Gastroenterological Association)
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in atopic dermatitis and allergic rhinitis but not asthma.78
This finding clearly needs to be explored further in other
atopic populations.
THE FUTURE
What are the prospects of translating this scientific progress
to clinical application? Although many unanswered ques-
tions exist, there is really a feeling of optimism among
clinicians and scientists following this recent progress.
Clearly further studies of gene function—genotype-pheno-
type relations, and gene-gene and gene-environmental
interactions need to be carried out. However, the increased
understanding of disease pathophysiology is likely to impact
on clinical practice.
Patient counselling may well be improved, when more
genetic data are available. The choice of drug therapies for an
individual patient may be rationalised, on the basis of
genotype. Already, some examples of this exist in inflamma-
tory bowel disease—the use of thiopurine methyltransferase
genotyping or phenotyping in patients receiving azathio-
prine.79 NOD 2/CARD 15 genotyping of patients requiring
infliximab therapy for refractory Crohn’s disease has not
been shown to be predictive of response.80 81
The continuing hope for all involved—clinicians, and
children with inflammatory bowel disease and their
families—is that this progress will lead to novel therapies,
with greater efficacy and safety than the current medical and
surgical therapy. This has now become a realistic prospect.
Progress is awaited eagerly and impatiently.
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